Access to effective FIP antiviral treatment varies globally, with regulatory barriers limiting availability of life-saving medication in some countries.
The transformation of FIP from universally fatal to largely treatable creates new welfare inequities based on geography and economics. Cats in countries without licensed access or owners without financial resources die preventably from FIP while treatment is available elsewhere. The regulatory lag between efficacy evidence and licensing creates a window of preventable suffering. Advocacy for expanded access and affordable generic options directly addresses this welfare gap.